| アブストラクト | In this article, we have carefully read the author's comments on our published article regarding the post-marketing safety concerns of lecanemab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Pharmacovigilance studies based on the disproportionality analysis through the case/non-case design are common, and the details of this method deserve attention. We acknowledged the author's perspectives on the term "signal of disproportionate reporting (SDR)", and make some explanations on the SDR results for pancreatic carcinoma and the deduplication methods. |
|---|
| ジャーナル名 | Alzheimer's research & therapy |
|---|
| Pubmed追加日 | 2025/4/9 |
|---|
| 投稿者 | Xing, Xiaoxuan; Wang, Ke; Dong, Xianzhe |
|---|
| 組織名 | Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45,;Changchun Street, Xicheng District, Beijing, P R China.;National Clinical Research Center for Geriatric Disorders, Beijing, China.;Changchun Street, Xicheng District, Beijing, P R China. dongxianzhe@xwhosp.org.;dongxianzhe@xwhosp.org. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40200347/ |
|---|
